CLAIMS

1. A combination comprising (3*S*, 11a*R*)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo- oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine.

2. Use of (3*S*, 11a*R*)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo- oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof, with rilpivirine in the manufacture of a medicament for treatment of HIV infection.

3. The use according to Claim 2, wherein the compounds are to be administered simultaneously.

4. The use according to Claim 2, wherein the compounds are to be administered sequentially.

5. A combination comprising (3*S*, 11a*R*)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo- oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine for use in treatment of HIV infection.

6. The combination for use according to claim 5, wherein (3*S*, 11a*R*)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo- oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine, are to be administered simultaneously.

7. The combination for use according to claim 5, wherein the compound of formula (3*S*, 11a*R*)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo- oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine, are to be administered sequentially.